Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1999 entries
Sorted by: Best Match Show Resources per page
Repetitive head impact exposure and later-life plasma total tau in former National Football League players.

Alzheimer's & dementia (Amsterdam, Netherlands)

Alosco ML, Tripodis Y, Jarnagin J, Baugh CM, Martin B, Chaisson CE, Estochen N, Song L, Cantu RC, Jeromin A, Stern RA.
PMID: 28229128
Alzheimers Dement (Amst). 2016 Dec 10;7:33-40. doi: 10.1016/j.dadm.2016.11.003. eCollection 2017.

INTRODUCTION: Blood protein analysis of total tau (t-tau) may be a practical screening biomarker for chronic traumatic encephalopathy (CTE), a neurodegenerative tauopathy associated with repetitive head impact (RHI) exposure. We examined plasma t-tau in symptomatic former National Football League...

Cite
Alosco ML, Tripodis Y, Jarnagin J, et al. Repetitive head impact exposure and later-life plasma total tau in former National Football League players. Alzheimers Dement (Amst). 2016;7:33-40doi: 10.1016/j.dadm.2016.11.003.
Alosco, M. L., Tripodis, Y., Jarnagin, J., Baugh, C. M., Martin, B., Chaisson, C. E., Estochen, N., Song, L., Cantu, R. C., Jeromin, A., & Stern, R. A. (2017). Repetitive head impact exposure and later-life plasma total tau in former National Football League players. Alzheimer's & dementia (Amsterdam, Netherlands), 733-40. https://doi.org/10.1016/j.dadm.2016.11.003
Alosco, Michael L, et al. "Repetitive head impact exposure and later-life plasma total tau in former National Football League players." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 7 (2017): 33-40. doi: https://doi.org/10.1016/j.dadm.2016.11.003
Alosco ML, Tripodis Y, Jarnagin J, Baugh CM, Martin B, Chaisson CE, Estochen N, Song L, Cantu RC, Jeromin A, Stern RA. Repetitive head impact exposure and later-life plasma total tau in former National Football League players. Alzheimers Dement (Amst). 2016 Dec 10;7:33-40. doi: 10.1016/j.dadm.2016.11.003. eCollection 2017. PMID: 28229128; PMCID: PMC5312499.
Copy Download .nbib Format: NLM
Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome.

Alzheimer's & dementia (Amsterdam, Netherlands)

Dekker AD, Fortea J, Blesa R, De Deyn PP.
PMID: 28413821
Alzheimers Dement (Amst). 2017 Mar 20;8:1-10. doi: 10.1016/j.dadm.2017.02.006. eCollection 2017.

Down syndrome (DS), present in nearly six million people, is associated with an extremely high risk to develop Alzheimer's disease (AD). Amyloid-β and tau pathology are omnipresent from age 40 years onward, but clinical symptoms do not appear in...

Cite
Dekker AD, Fortea J, Blesa R, et al. Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. Alzheimers Dement (Amst). 2017;8:1-10doi: 10.1016/j.dadm.2017.02.006.
Dekker, A. D., Fortea, J., Blesa, R., & De Deyn, P. P. (2017). Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. Alzheimer's & dementia (Amsterdam, Netherlands), 81-10. https://doi.org/10.1016/j.dadm.2017.02.006
Dekker, Alain D, et al. "Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 8 (2017): 1-10. doi: https://doi.org/10.1016/j.dadm.2017.02.006
Dekker AD, Fortea J, Blesa R, De Deyn PP. Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. Alzheimers Dement (Amst). 2017 Mar 20;8:1-10. doi: 10.1016/j.dadm.2017.02.006. eCollection 2017. PMID: 28413821; PMCID: PMC5384293.
Copy Download .nbib Format: NLM
The Effect of Statins on Rate of Cognitive Decline in Mild Cognitive Impairment.

Alzheimer's & dementia (New York, N. Y.)

Smith KB, Kang P, Sabbagh MN.
PMID: 28480324
Alzheimers Dement (N Y). 2017 Jun;3(2):149-156. doi: 10.1016/j.trci.2017.01.001.

OBJECTIVE: This study's aims are to identify whether or not a relationship between statin use and rate of cognitive decline exists.BACKGROUND: The relationship between statins and MCI has been investigated in the past with the evidence showing mixed results.METHODS:...

Cite
Smith KB, Kang P, Sabbagh MN. The Effect of Statins on Rate of Cognitive Decline in Mild Cognitive Impairment. Alzheimers Dement (N Y). 2017;3(2):149-156doi: 10.1016/j.trci.2017.01.001.
Smith, K. B., Kang, P., Sabbagh, M. N. (2017). The Effect of Statins on Rate of Cognitive Decline in Mild Cognitive Impairment. Alzheimer's & dementia (New York, N. Y.), 3(2), 149-156. https://doi.org/10.1016/j.trci.2017.01.001
Smith, Kyle B, et al. "The Effect of Statins on Rate of Cognitive Decline in Mild Cognitive Impairment." Alzheimer's & dementia (New York, N. Y.) vol. 3,2 (2017): 149-156. doi: https://doi.org/10.1016/j.trci.2017.01.001
Smith KB, Kang P, Sabbagh MN. The Effect of Statins on Rate of Cognitive Decline in Mild Cognitive Impairment. Alzheimers Dement (N Y). 2017 Jun;3(2):149-156. doi: 10.1016/j.trci.2017.01.001. PMID: 28480324; PMCID: PMC5412714.
Copy Download .nbib Format: NLM
Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma.

Alzheimer's & dementia (Amsterdam, Netherlands)

Koch M, Furtado JD, Falk K, Leypoldt F, Mukamal KJ, Jensen MK.
PMID: 28289700
Alzheimers Dement (Amst). 2017 Feb 24;6:182-187. doi: 10.1016/j.dadm.2017.01.007. eCollection 2017.

INTRODUCTION: Subspecies of apolipoproteins can be defined by fractionating apolipoproteins based on the presence and absence of coexisting apolipoproteins.METHODS: We determined age- and sex-adjusted correlations of enzyme-linked immunosorbent assay-measured plasma and cerebrospinal fluid (CSF) apolipoproteins (apoA-I, apoC-III, apoE, and...

Cite
Koch M, Furtado JD, Falk K, et al. Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma. Alzheimers Dement (Amst). 2017;6:182-187doi: 10.1016/j.dadm.2017.01.007.
Koch, M., Furtado, J. D., Falk, K., Leypoldt, F., Mukamal, K. J., & Jensen, M. K. (2017). Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma. Alzheimer's & dementia (Amsterdam, Netherlands), 6182-187. https://doi.org/10.1016/j.dadm.2017.01.007
Koch, Manja, et al. "Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 6 (2017): 182-187. doi: https://doi.org/10.1016/j.dadm.2017.01.007
Koch M, Furtado JD, Falk K, Leypoldt F, Mukamal KJ, Jensen MK. Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma. Alzheimers Dement (Amst). 2017 Feb 24;6:182-187. doi: 10.1016/j.dadm.2017.01.007. eCollection 2017. PMID: 28289700; PMCID: PMC5338868.
Copy Download .nbib Format: NLM
Intermittent hypoxic-hyperoxic training on cognitive performance in geriatric patients.

Alzheimer's & dementia (New York, N. Y.)

Bayer U, Likar R, Pinter G, Stettner H, Demschar S, Trummer B, Neuwersch S, Glazachev O, Burtscher M.
PMID: 29067323
Alzheimers Dement (N Y). 2017 Feb 08;3(1):114-122. doi: 10.1016/j.trci.2017.01.002. eCollection 2017 Jan.

INTRODUCTION: Intermittent hypoxic-hyperoxic training (IHHT) may complement a multimodal training intervention (MTI) for improving cognitive function and exercise tolerance in geriatric patients.METHODS: Thirty-four patients (64-92 years) participated in this randomized controlled trial. Before and after the 5- to 7-week...

Cite
Bayer U, Likar R, Pinter G, et al. Intermittent hypoxic-hyperoxic training on cognitive performance in geriatric patients. Alzheimers Dement (N Y). 2017;3(1):114-122doi: 10.1016/j.trci.2017.01.002.
Bayer, U., Likar, R., Pinter, G., Stettner, H., Demschar, S., Trummer, B., Neuwersch, S., Glazachev, O., & Burtscher, M. (2017). Intermittent hypoxic-hyperoxic training on cognitive performance in geriatric patients. Alzheimer's & dementia (New York, N. Y.), 3(1), 114-122. https://doi.org/10.1016/j.trci.2017.01.002
Bayer, Urike, et al. "Intermittent hypoxic-hyperoxic training on cognitive performance in geriatric patients." Alzheimer's & dementia (New York, N. Y.) vol. 3,1 (2017): 114-122. doi: https://doi.org/10.1016/j.trci.2017.01.002
Bayer U, Likar R, Pinter G, Stettner H, Demschar S, Trummer B, Neuwersch S, Glazachev O, Burtscher M. Intermittent hypoxic-hyperoxic training on cognitive performance in geriatric patients. Alzheimers Dement (N Y). 2017 Feb 08;3(1):114-122. doi: 10.1016/j.trci.2017.01.002. eCollection 2017 Jan. PMID: 29067323; PMCID: PMC5651371.
Copy Download .nbib Format: NLM
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy.

Alzheimer's & dementia (New York, N. Y.)

Landen JW, Cohen S, Billing CB, Cronenberger C, Styren S, Burstein AH, Sattler C, Lee JH, Jack CR, Kantarci K, Schwartz PF, Duggan WT, Zhao Q, Sprenger K, Bednar MM, Binneman B.
PMID: 29067341
Alzheimers Dement (N Y). 2017 May 10;3(3):339-347. doi: 10.1016/j.trci.2017.04.003. eCollection 2017 Sep.

INTRODUCTION: Multiple intravenous doses of ponezumab, an anti-amyloid antibody, were evaluated in subjects with mild-to-moderate Alzheimer's disease (AD).METHODS: In part A, 77 subjects were randomized to ponezumab 0.1, 0.5, or 1 mg/kg (75 treated) and 26 to placebo (24...

Cite
Landen JW, Cohen S, Billing CB, et al. Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy. Alzheimers Dement (N Y). 2017;3(3):339-347doi: 10.1016/j.trci.2017.04.003.
Landen, J. W., Cohen, S., Billing, C. B., Cronenberger, C., Styren, S., Burstein, A. H., Sattler, C., Lee, J. H., Jack, C. R., Kantarci, K., Schwartz, P. F., Duggan, W. T., Zhao, Q., Sprenger, K., Bednar, M. M., & Binneman, B. (2017). Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy. Alzheimer's & dementia (New York, N. Y.), 3(3), 339-347. https://doi.org/10.1016/j.trci.2017.04.003
Landen, Jaren W, et al. "Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy." Alzheimer's & dementia (New York, N. Y.) vol. 3,3 (2017): 339-347. doi: https://doi.org/10.1016/j.trci.2017.04.003
Landen JW, Cohen S, Billing CB, Cronenberger C, Styren S, Burstein AH, Sattler C, Lee JH, Jack CR, Kantarci K, Schwartz PF, Duggan WT, Zhao Q, Sprenger K, Bednar MM, Binneman B. Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy. Alzheimers Dement (N Y). 2017 May 10;3(3):339-347. doi: 10.1016/j.trci.2017.04.003. eCollection 2017 Sep. PMID: 29067341; PMCID: PMC5651443.
Copy Download .nbib Format: NLM
Impact of programs to reduce antipsychotic and anticholinergic use in nursing homes.

Alzheimer's & dementia (New York, N. Y.)

Carnahan RM, Brown GD, Letuchy EM, Rubenstein LM, Gryzlak BM, Smith M, Reist JC, Kelly MW, Schultz SK, Weckmann MT, Chrischilles EA.
PMID: 29124114
Alzheimers Dement (N Y). 2017 Mar 06;3(4):553-561. doi: 10.1016/j.trci.2017.02.003. eCollection 2017 Nov.

INTRODUCTION: Antipsychotics are used for managing behavioral and psychological symptoms of dementia (BPSD) but have risks. Anticholinergics can worsen outcomes in dementia. The Improving Antipsychotic Appropriateness in Dementia Patients educational program (IA-ADAPT) and Centers for Medicare and Medicaid Services...

Cite
Carnahan RM, Brown GD, Letuchy EM, et al. Impact of programs to reduce antipsychotic and anticholinergic use in nursing homes. Alzheimers Dement (N Y). 2017;3(4):553-561doi: 10.1016/j.trci.2017.02.003.
Carnahan, R. M., Brown, G. D., Letuchy, E. M., Rubenstein, L. M., Gryzlak, B. M., Smith, M., Reist, J. C., Kelly, M. W., Schultz, S. K., Weckmann, M. T., & Chrischilles, E. A. (2017). Impact of programs to reduce antipsychotic and anticholinergic use in nursing homes. Alzheimer's & dementia (New York, N. Y.), 3(4), 553-561. https://doi.org/10.1016/j.trci.2017.02.003
Carnahan, Ryan M, et al. "Impact of programs to reduce antipsychotic and anticholinergic use in nursing homes." Alzheimer's & dementia (New York, N. Y.) vol. 3,4 (2017): 553-561. doi: https://doi.org/10.1016/j.trci.2017.02.003
Carnahan RM, Brown GD, Letuchy EM, Rubenstein LM, Gryzlak BM, Smith M, Reist JC, Kelly MW, Schultz SK, Weckmann MT, Chrischilles EA. Impact of programs to reduce antipsychotic and anticholinergic use in nursing homes. Alzheimers Dement (N Y). 2017 Mar 06;3(4):553-561. doi: 10.1016/j.trci.2017.02.003. eCollection 2017 Nov. PMID: 29124114; PMCID: PMC5671632.
Copy Download .nbib Format: NLM
Assessing risk for preclinical β-amyloid pathology with .

Alzheimer's & dementia (Amsterdam, Netherlands)

Insel PS, Palmqvist S, Mackin RS, Nosheny RL, Hansson O, Weiner MW, Mattsson N.
PMID: 27722193
Alzheimers Dement (Amst). 2016 Aug 03;4:76-84. doi: 10.1016/j.dadm.2016.07.002. eCollection 2016.

INTRODUCTION: Clinical trials in Alzheimer's disease are aimed at early stages of disease, including preclinical Alzheimer's disease. The high cost and time required to screen large numbers of participants for Aβ pathology impede the development of novel drugs. This...

Cite
Insel PS, Palmqvist S, Mackin RS, et al. Assessing risk for preclinical β-amyloid pathology with . Alzheimers Dement (Amst). 2016;4:76-84doi: 10.1016/j.dadm.2016.07.002.
Insel, P. S., Palmqvist, S., Mackin, R. S., Nosheny, R. L., Hansson, O., Weiner, M. W., & Mattsson, N. (2016). Assessing risk for preclinical β-amyloid pathology with . Alzheimer's & dementia (Amsterdam, Netherlands), 476-84. https://doi.org/10.1016/j.dadm.2016.07.002
Insel, Philip S, et al. "Assessing risk for preclinical β-amyloid pathology with ." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 4 (2016): 76-84. doi: https://doi.org/10.1016/j.dadm.2016.07.002
Insel PS, Palmqvist S, Mackin RS, Nosheny RL, Hansson O, Weiner MW, Mattsson N. Assessing risk for preclinical β-amyloid pathology with . Alzheimers Dement (Amst). 2016 Aug 03;4:76-84. doi: 10.1016/j.dadm.2016.07.002. eCollection 2016. PMID: 27722193; PMCID: PMC5045949.
Copy Download .nbib Format: NLM
Assessing reliability of short and tick box forms of the ANU-ADRI: Convenient alternatives of a self-report Alzheimer's disease risk assessment.

Alzheimer's & dementia (New York, N. Y.)

Kim S, Cherbuin N, Anstey KJ.
PMID: 29067296
Alzheimers Dement (N Y). 2016 Apr 03;2(2):93-98. doi: 10.1016/j.trci.2016.03.001. eCollection 2016 Jun.

INTRODUCTION: To assess the reliability of short versions of the Australian National University Alzheimer's Disease Risk Index (ANU-ADRI).METHODS: A short form of the ANU-ADRI (ANU-ADRI-SF) was developed by assessing risk and protective factors with single questions where possible and...

Cite
Kim S, Cherbuin N, Anstey KJ. Assessing reliability of short and tick box forms of the ANU-ADRI: Convenient alternatives of a self-report Alzheimer's disease risk assessment. Alzheimers Dement (N Y). 2016;2(2):93-98doi: 10.1016/j.trci.2016.03.001.
Kim, S., Cherbuin, N., & Anstey, K. J. (2016). Assessing reliability of short and tick box forms of the ANU-ADRI: Convenient alternatives of a self-report Alzheimer's disease risk assessment. Alzheimer's & dementia (New York, N. Y.), 2(2), 93-98. https://doi.org/10.1016/j.trci.2016.03.001
Kim, Sarang, et al. "Assessing reliability of short and tick box forms of the ANU-ADRI: Convenient alternatives of a self-report Alzheimer's disease risk assessment." Alzheimer's & dementia (New York, N. Y.) vol. 2,2 (2016): 93-98. doi: https://doi.org/10.1016/j.trci.2016.03.001
Kim S, Cherbuin N, Anstey KJ. Assessing reliability of short and tick box forms of the ANU-ADRI: Convenient alternatives of a self-report Alzheimer's disease risk assessment. Alzheimers Dement (N Y). 2016 Apr 03;2(2):93-98. doi: 10.1016/j.trci.2016.03.001. eCollection 2016 Jun. PMID: 29067296; PMCID: PMC5644274.
Copy Download .nbib Format: NLM
A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects.

Alzheimer's & dementia (New York, N. Y.)

Ghosal K, Haag M, Verghese PB, West T, Veenstra T, Braunstein JB, Bateman RJ, Holtzman DM, Landreth GE.
PMID: 29067298
Alzheimers Dement (N Y). 2016 Jun 17;2(2):110-120. doi: 10.1016/j.trci.2016.06.001. eCollection 2016 Jun.

INTRODUCTION: We conducted a phase Ib proof of mechanism trial to determine whether bexarotene (Targretin) increases central nervous system (CNS) apolipoprotein E (apoE) levels and alters Aβ metabolism in normal healthy individuals with the METHODS: We used stable isotope...

Cite
Ghosal K, Haag M, Verghese PB, et al. A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects. Alzheimers Dement (N Y). 2016;2(2):110-120doi: 10.1016/j.trci.2016.06.001.
Ghosal, K., Haag, M., Verghese, P. B., West, T., Veenstra, T., Braunstein, J. B., Bateman, R. J., Holtzman, D. M., & Landreth, G. E. (2016). A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects. Alzheimer's & dementia (New York, N. Y.), 2(2), 110-120. https://doi.org/10.1016/j.trci.2016.06.001
Ghosal, Kaushik, et al. "A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects." Alzheimer's & dementia (New York, N. Y.) vol. 2,2 (2016): 110-120. doi: https://doi.org/10.1016/j.trci.2016.06.001
Ghosal K, Haag M, Verghese PB, West T, Veenstra T, Braunstein JB, Bateman RJ, Holtzman DM, Landreth GE. A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects. Alzheimers Dement (N Y). 2016 Jun 17;2(2):110-120. doi: 10.1016/j.trci.2016.06.001. eCollection 2016 Jun. PMID: 29067298; PMCID: PMC5644280.
Copy Download .nbib Format: NLM
Poor cerebrovascular function is an early marker of cognitive decline in healthy postmenopausal women.

Alzheimer's & dementia (New York, N. Y.)

Wong RHX, Evans HM, Howe PRC.
PMID: 29067303
Alzheimers Dement (N Y). 2016 Aug 03;2(3):162-168. doi: 10.1016/j.trci.2016.07.003. eCollection 2016 Sep.

INTRODUCTION: Impairment of cerebrovascular function becomes evident after menopause. No study has yet explored relationships between deficits in cerebrovascular function, cognitive performance, and mood in postmenopausal women.METHOD: Cerebrovascular function was assessed in 80 healthy postmenopausal women by monitoring blood...

Cite
Wong RHX, Evans HM, Howe PRC. Poor cerebrovascular function is an early marker of cognitive decline in healthy postmenopausal women. Alzheimers Dement (N Y). 2016;2(3):162-168doi: 10.1016/j.trci.2016.07.003.
Wong, R. H. X., Evans, H. M., & Howe, P. R. C. (2016). Poor cerebrovascular function is an early marker of cognitive decline in healthy postmenopausal women. Alzheimer's & dementia (New York, N. Y.), 2(3), 162-168. https://doi.org/10.1016/j.trci.2016.07.003
Wong, Rachel H X, et al. "Poor cerebrovascular function is an early marker of cognitive decline in healthy postmenopausal women." Alzheimer's & dementia (New York, N. Y.) vol. 2,3 (2016): 162-168. doi: https://doi.org/10.1016/j.trci.2016.07.003
Wong RHX, Evans HM, Howe PRC. Poor cerebrovascular function is an early marker of cognitive decline in healthy postmenopausal women. Alzheimers Dement (N Y). 2016 Aug 03;2(3):162-168. doi: 10.1016/j.trci.2016.07.003. eCollection 2016 Sep. PMID: 29067303; PMCID: PMC5651351.
Copy Download .nbib Format: NLM
Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor.

Alzheimer's & dementia (New York, N. Y.)

Timmers M, Van Broeck B, Ramael S, Slemmon J, De Waepenaert K, Russu A, Bogert J, Stieltjes H, Shaw LM, Engelborghs S, Moechars D, Mercken M, Liu E, Sinha V, Kemp J, Van Nueten L, Tritsmans L, Streffer JR.
PMID: 29067308
Alzheimers Dement (N Y). 2016 Aug 24;2(3):202-212. doi: 10.1016/j.trci.2016.08.001. eCollection 2016 Sep.

OBJECTIVES: Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, JNJ-54861911, were assessed after single and multiple dosing in healthy participants.METHODS: Two randomized, placebo-controlled, double-blind studies were performed using single and...

Cite
Timmers M, Van Broeck B, Ramael S, et al. Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. Alzheimers Dement (N Y). 2016;2(3):202-212doi: 10.1016/j.trci.2016.08.001.
Timmers, M., Van Broeck, B., Ramael, S., Slemmon, J., De Waepenaert, K., Russu, A., Bogert, J., Stieltjes, H., Shaw, L. M., Engelborghs, S., Moechars, D., Mercken, M., Liu, E., Sinha, V., Kemp, J., Van Nueten, L., Tritsmans, L., & Streffer, J. R. (2016). Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. Alzheimer's & dementia (New York, N. Y.), 2(3), 202-212. https://doi.org/10.1016/j.trci.2016.08.001
Timmers, Maarten, et al. "Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor." Alzheimer's & dementia (New York, N. Y.) vol. 2,3 (2016): 202-212. doi: https://doi.org/10.1016/j.trci.2016.08.001
Timmers M, Van Broeck B, Ramael S, Slemmon J, De Waepenaert K, Russu A, Bogert J, Stieltjes H, Shaw LM, Engelborghs S, Moechars D, Mercken M, Liu E, Sinha V, Kemp J, Van Nueten L, Tritsmans L, Streffer JR. Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. Alzheimers Dement (N Y). 2016 Aug 24;2(3):202-212. doi: 10.1016/j.trci.2016.08.001. eCollection 2016 Sep. PMID: 29067308; PMCID: PMC5651349.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1999 entries